A phase I study of reolysin given intravenously to patients with advanced malignancies.

被引：0
|
作者：
Vidal, L.
Pandha, H.
Spicer, J.
Harrington, K. J.
Allen, S.
Leader, D.
Coffey, M.
Thompson, B.
Kaye, S.
De-Bono, J.
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Univ London St Georges Hosp, Sch Med, London SW17 0RE, England
[3] Oncolyt Biotech Inc, Calgary, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：136S / 136S
页数：1
相关论文
共 50 条
  • [1] A phase I study of a wild-type reovirus (Reolysin) given intravenously to patients with advanced malignancies.
    Vidal, L
    Pandha, H
    Harrington, K
    Fong, P
    Shaw, H
    Barrett, M
    Leader, D
    White, C
    Twigger, K
    Coffey, M
    Thompson, B
    Kaye, S
    De-Bono, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9106S - 9107S
  • [2] Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies.
    Faivre, SJ
    Delbaldo, C
    Pautier, P
    Boige, V
    Henriet, S
    Armand, JP
    Grau, B
    Namouni, F
    Peck, R
    Raymond, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [3] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.
    Cohen, E. E.
    Sharma, M.
    Janisch, L. A.
    Stadler, W. M.
    Kang, S. P.
    Fleming, G. F.
    Ratain, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I study of BMS-188797, a new taxane analog, given weekly in patients with advanced malignancies.
    Goldstein, L
    Vaders, L
    Rogatko, A
    Bulanhagui, C
    Gupta, E
    Tarby, C
    Sonnichsen, D
    Gustafson, N
    Gallant, G
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4579S - 4579S
  • [5] Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.
    Mittal, Kriti
    Koon, Henry B.
    Elson, Paul
    Triozzi, Pierre L.
    Dowlati, Afshin
    Borden, Ernest C.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I study of RFS 2000 and gemcitabine (Gem) in patients with advanced malignancies.
    Fracasso, PM
    Tan, BR
    Sun, SL
    Revell, SM
    Lenaz, L
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4515S - 4515S
  • [7] A PHASE I STUDY TO ASSESS FOOD EFFECT ON OPROZOMIB IN PATIENTS WITH ADVANCED MALIGNANCIES.
    Harvey, R. D.
    Gore, L.
    Wang, D.
    Mita, A.
    Sharma, S.
    Nemunaitis, J.
    Papadopoulos, K.
    Pinchasik, D.
    Ou, Y.
    Demirhan, E.
    Cutler, R. E., Jr.
    Tsimberidou, A. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S98 - S99
  • [8] Brequinar in combination with cisplatin in patients with advanced malignancies. A phase I study with pharmacokinetics
    Burris, A
    Raymond, E
    Awada, A
    Kuhn, J
    O'Rourke, J
    Brentzel, J
    Lynch, W
    King, SY
    Brown, T
    Von Hoff, D
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 125 - 125
  • [9] A phase I study of the heparanase inhibitor PI-88 given subcutaneously (SQ) in patients (pts) with advanced solid malignancies.
    Basche, M
    Eckhardt, SG
    O'Bryant, CL
    Gore, L
    Witta, S
    Raj, S
    Schultz, MK
    Persky, M
    Morrow, M
    Grolnic, S
    Hunt, JE
    Creese, B
    Kangas, M
    Roberts, K
    Sawlwin, D
    Moore, J
    Holden, SN
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6140S - 6140S
  • [10] Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.
    Springett, GM
    Takimoto, C
    McNamara, M
    Doroshow, JH
    Syed, S
    Eastham, E
    Spriggs, D
    Pezzulli, S
    Michelson, G
    Dupont, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 226S - 226S
12345